|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To gain insight into RASSF1A functions in an unbiased manner, we have characterized the expression profile of a lung cancer cell line (A549) transfected with RASSF1A.
|
14500366 |
2003 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the study was to explore the application of artificial neural network model in the auxiliary diagnosis of lung cancer and compare the effects of back-propagation (BP) neural network with Fisher discrimination model for lung cancer screening by the combined detections of four biomarkers of p16, RASSF1A and FHIT gene promoter methylation levels and the relative telomere length.
|
27766520 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the high methylation statuses of p16, RASSF1A, or FHIT genes were associated with a significantly increased risk of lung cancer; the risk of lung cancer increased as the methylation status increased.
|
23614702 |
2013 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previously, the RASSF1A, BLU and SEMAPHORIN 3B (SEMA3B) candidate tumor suppressor genes on chromosome 3p21.3 were found to be inactivated and downregulated by genetic and epigenetic changes in lung cancer.
|
15704097 |
2005 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A is validated as diagnostic marker in lung cancer.
|
25719833 |
2015 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RT-PCR analysis showed no expression of RASSF1A in 12 of 20 lung cancer cell lines.
|
12794755 |
2003 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings suggest that RASSF1C, unlike RASSF1A, is not a tumor suppressor but rather stimulates lung cancer cell proliferation.
|
16891396 |
2006 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that serum RASSF1A hypermethylation is a promising molecular biomarker for lung cancer diagnosis.
|
17267069 |
2007 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Inactivation of the tumor suppressor gene RASSF1A by promoter hypermethylation represents a key event underlying the initiation and progression of lung cancer.
|
26759237 |
2016 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A is one of the tumor suppressor genes, and it is frequently inactivated by hypermethylation of its promoter region in a variety of human cancers, including lung cancer.
|
15700308 |
2005 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using quantitative methylation-specific PCR, we found that the index of methylation (IM), calculated as IM = 100 × [copy number of methylated/(copy number of methylated + unmethylated gene)], for the RASSF1A and RARB2 genes in the cirDNA isolated from blood plasma and cell-surface-bound cirDNA was elevated 2- to 3-fold in lung cancer patients compared with healthy donors.
|
23806794 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT).
|
30979377 |
2019 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of DeltaDNMT3B4 expression by small interfering RNA resulted in a rapid demethylation of RASSF1A promoter and reexpression of RASSF1A mRNA but had no effect on p16 promoter in the lung cancer cells.
|
18006804 |
2007 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
|
12101420 |
2002 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study examined effects of cigarette smoke condensate (CSC) on expression and promoter methylation profile of critical genes (DAPK, ECAD, MGMT, and RASSF1A) involved in lung cancer development in different human lung cell lines.
|
23174910 |
2013 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk model showed that 36% of lung cancer patients were defined as "high risk" (≥ 60% chance on lung cancer) based on RASSF1A hypermethylation in Set 1.The model was reproducible in Set 2.
|
24598366 |
2014 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic value in early lung cancer detection.
|
16152615 |
2006 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
L1RE1 in combination with either RARB or RASSF1 could function as biomarkers for separating lung cancer and non-cancerous tissue and could be useful for samples of limited size such as biopsies.
|
29851970 |
2018 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ras association domain family 1A (RASSF1A), a pivotal gatekeeper of cell cycle progression, is highly methylated in a wide range of human sporadic tumors, including lung cancer.
|
21971684 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the diagnostic utility of the SHOX2 assay was tested with regard to cytology for different cytological diagnostic categories to assess whether it can complement the cytological examination and the DNA methylation marker panel targeting the gene promoters of adenomatous polyposis coli 1A (APC), cyclin-dependent kinase inhibitor-2A (p16(INK4A)) and Ras association domain family protein 1 (RASSF1A) regarding lung cancer detection in bronchial aspirates.
|
25331797 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
FUS1, NPRL2/G21 and RASSF1A are TSGs from LUCA region at 3p21.3, a critical chromosomal region in lung cancer development.
|
26112163 |
2015 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, knockdown of DNMT1 by siRNA <i>in vivo</i> also effectively demethylated the RASSF1A and APC promoter, elevated their expressions and limited tumor growth, which functioned like 5-Aza-CR but with alleviated side effects, suggesting that knockdown of DNMT1 might be potential strategy for the treatment of lung cancer with better tolerability.
|
28938637 |
2017 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We find that lung cancer cells with RASSF1A promoter methylation display constitutive nuclear YAP1 accumulation and expression of prolyl 4-hydroxylase alpha-2 (P4HA2) which increases collagen deposition.
|
31268606 |
2019 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Overall, a significant relationship between RASSF1A promoter methylation and lung cancer risk (OR, 16.12; 95%CI, 11.40-22.81; p<0.001) with no between-study heterogeneity.
|
25556469 |
2014 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
When used in concert, RASSF1A hypermethylation in sputum and exhaled breath analysis are complementary for lung cancer diagnosis, with 100% sensitivity in this series.
|
24915850 |
2014 |